Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Limited has applied for quotation on the ASX of 300,137 new fully paid ordinary shares under code RHY. The new securities, issued on 20 February 2026 following the exercise or conversion of existing options or other convertible instruments, will modestly increase the company’s listed share capital and may have a small dilutive effect for existing shareholders.
The application, lodged as an Appendix 2A new announcement, reflects routine capital management activity within the company’s ASX listing framework. While the release does not provide operational or strategic updates, it signals continued engagement with capital markets and incremental expansion of Rhythm Biosciences’ equity base.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Limited is an Australia-based biotechnology company listed on the ASX under the ticker RHY. The company operates in the medical and life sciences sector, though this filing provides only corporate and capital markets information rather than product or market details.
Average Trading Volume: 946,912
Technical Sentiment Signal: Buy
Current Market Cap: A$70.83M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.